News

Interim results from the study indicate that significantly higher anti-nicotine antibody levels can be generated three months earlier and in a much higher percentage of subjects than observed

The Phase III Glass-Art trial is designed to determine the survival benefit derived from, and safety of, adding Neuradiab to the current standard of care therapy, consisting of

To evaluate the role of norepinephrine (NE) in fibromyalgia and the safety and efficacy of Droxidopa in this indication, Chelsea intends to conduct an exploratory Phase II trial

The first agreement with the University of Louisville’s James Graham Brown Cancer Center grants Advanced Cancer Therapeutics (ACT) exclusive worldwide development and commercialization rights to monovalent vaccines derived

Michael DeLaGarza, president and CEO of AMSS and PayMed, will assume the position of president of MedCom USA, once the acquisition is finalized. He has worked in the

Under the agreement Novartis will provide Dynavax a supply of trivalent influenza vaccine, an essential component of Dynavax’s Universal Influenza Vaccine, for both clinical trial use and vaccine

Under the terms of the agreement, Spiration and Olympus will work exclusively with each other to gain regulatory approval for the IBV valve system in Japan. Olympus will

ImmunoCellular Therapeutics (IMUC) is advancing its monoclonal antibodies toward clinical trials, and humanizing the antibodies will provide for a safer therapeutic with less immunogenicity potential. IMUC, through its

The study showed that treatment of hormone resistant human prostate cancer in tumor bearing mouse models with intravenous pegylated-rHuPH20 enzyme (PEGPH20) in combination with the chemotherapeutic drugs, docetaxel